Dr. Reddy's Laboratories Limited EBIT

The latest EBIT for DRREDDY.NS is $35B as of June 2026. That compares with $80B in the prior-year period — down 56.7% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Dr. Reddy's Laboratories Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, DRREDDY.NS's EBIT moved from $80B to $35B — a 56.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Dr. Reddy's Laboratories Limited's operating scale or balance-sheet position.

Against Healthcare companies, DRREDDY.NS currently prints $35B for EBIT, while the sector average sits near $130B. That is roughly 74.1% below the sector mean. Large gaps often invite a closer look at Dr. Reddy's Laboratories Limited's growth, margins, and balance sheet.

A EBIT figure of $35B for DRREDDY.NS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting DRREDDY.NS's EBIT ($35B), review year-over-year change from $80B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.